New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
09:21 EDTEXASFDA says Exact Sciences colorectal cancer screening tool study met objectives
Exact Sciences' Deep-C study met the primary objectives with respect to both required sensitivity and specificity of the company's Cologuard test compared to colonoscopy, FDA staff wrote in briefing documents ahead of the March 27 meeting of the Molecular and Clinical Advisory Committee Panel. With respect to the secondary objectives, Cologuard sensitivity is higher than FIT for both CRC and AA, FDA staff noted. Cologuard is an in vitro diagnostic device designed to analyze patientsí stool for the presence of colorectal cancer. Reference Link
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
10:04 EDTEXASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:56 EDTEXASExact Sciences downgraded to Hold from Buy at Lake Street
Lake Street downgraded Exact Sciences to Hold with a $24 price target citing concerns over Cologuard'a ability to ramp quickly in the commercial insurance segment over the longer term.
08:46 EDTEXASExact Sciences price target raised to $31 from $27 at JMP Securities
Subscribe for More Information
May 4, 2015
05:11 EDTEXASExact Sciences reports Q1 EPS (40c), consensus (41c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use